Table 1. Summary of key favorable and unfavorable effects (Study D2308).
Subgroup of patients who received at least two prior regimens including bortezomib and an immunomodulating agent.
FAS population.
Abbreviations: BTZ, bortezomib; Dex, dexamethasone; FAS, full analysis set; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; PAN, panobinostat.